Clinical trials: Endocrine System Disorder
Unilateral Ovarian Endometrioma
Vasopressin Injection Technique to Preserve Ovarian Reserve in Surgery for Unilateral Ovarian Endometriomas
Endometriosis is a common disease with an incidence rate of 15% in women of childbearing age, and is a chronic disease that significantly affects women's quality of life by causing two problems: pain and infertility.
- Trial name
- NCT04372836
- Testing
- Vasopressin injection
- Where
- South Korea
- Volunteers
- 76 people
- Sponsor
- Yonsei University
Ovarian Epithelial Cancer
Timing of Surgery After Neoadjuvant Chemotherapy for Advanced Ovarian Cancer
Ovarian cancer is among the top five primary causes of cancer-related mortality in women. Most ovarian malignant tumours originate from epithelial cells The majority of patients typically have advanced-stage tumours at diagnosis.
- Trial name
- NCT06404671
- Testing
- Delayed interval cytoreductive surgery (DICS), Early interval cytoreductive surgery (EICS)
- Where
- Egypt
- Volunteers
- 250 people
- Sponsor
- Alexandria University
Diabetes, Diabetes Mellitus, Type 1
A Trial Assessing Changes in Blood Sugar and the Number of Periods Where Supplementation of Carbohydrate is Needed to Treat Low Blood Sugar, During Two Different Treatment Regimens of NN1250 in Type 1 Diabetics
This trial is conducted in Europe. The aim is to compare changes in blood sugar and the number of periods where carbohydrate supplementation is needed to treat low blood sugar, during two different treatments with NN1250 (insulin…
- Trial name
- NCT00964964
- Testing
- insulin degludec
- Where
- Germany
- Volunteers
- 18 people
- Sponsor
- Novo Nordisk A/S
Diabete Type 2
Safety, Tolerability and Efficacy of Semaglutide Depot in Subjects With Type-2 Diabetes Mellitus
Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is an approved and well-established therapy for type 2 diabetes mellitus (T2DM), providing both robust glycemic control and weight reduction.
- Trial name
- NCT07563699
- Testing
- SG Depot 2 mg, SG Depot 4 mg, SG Depot 6 mg
- Where
- Israel
- Volunteers
- 24 people
- Sponsor
- Mapi Pharma Ltd.
Diabetes Mellitus, Type 1
A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults
The purpose of this study is to find out if baricitinib can delay the onset of clinical type 1 diabetes (T1D) in people who are at high risk to develop T1D. Participation in the study will last up to approximately 5 years.
- Trial name
- BARICADE-DELAY (NCT07222137)
- Testing
- Baricitinib
- Where
- 112 sites in United States, Australia and 17 more
- Volunteers
- 150 people
- Sponsor
- Eli Lilly and Company
Type 1 Diabetes Mellitus
Impact of Optimized Titration and Delivery of Bedtime Insulin on Prevention of Nocturnal Hypoglycemia
The purpose of this study is to determine whether or not bedtime snacks are necessary to prevent overnight low blood glucose reactions (nocturnal hypoglycemia) in adults with type 1 diabetes who are using intensive insulin…
- Trial name
- NCT00475345
- Testing
- Bedtime snacks
- Where
- Canada
- Volunteers
- 29 people
- Sponsor
- McGill University
Thymoma, Stomach Neoplasms
Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma
Background: Malignant mesothelioma is a malignancy arising from the mesothelial cells of the pleura, peritoneum, pericardium, or tunica vaginalis. Mesothelioma accounts for 0.10% of deaths annually in the United States.
- Conditions
- Thymoma, Stomach Neoplasms, Pancreatic Neoplasms, Mesothelioma
- Trial name
- NCT01950572
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- National Cancer Institute (NCI)
Epithelial Ovarian Cancer, Relapse
Tri Association in Patient With Advanced Epithelial Ovarian Cancer in Relapse
Assessing the safety and efficacy of the bevacizumab, Olaparib and Durvalumab (MEDI 4736) combination in patient with high grade serous or high grade endometrioid or other high grade epithelial non mucinous ovarian tumor, with at…
- Trial name
- BOLD (NCT04015739)
- Testing
- Bevacizumab, Olaparib and Durvalumab (MEDI 4736) combination
- Where
- 9 sites in France
- Volunteers
- 74 people
- Sponsor
- ARCAGY/ GINECO GROUP
Type 2 Diabetes
A Study to Assess the Pharmacokinetics, Safety and Tolerability of Sitagliptin in Adolescents (0431-081)
This study will assess the safety, tolerability and pharmacokinetics of sitagliptin in 10 to 17 year old diabetic patients.
- Trial name
- NCT00730275
- Testing
- Sitagliptin phosphate
- Volunteers
- 35 people
- Sponsor
- Merck Sharp & Dohme LLC
Latent Autoimmune Diabetes in Adults (LADA)
Hybrid Closed-Loop System in LADA Patients: A Randomized Trial
Based on the difficulties in blood glucose control among the Latent Autoimmune Diabetes in Adults (LADA) population and the deficiencies of previous studies, this research aims to conduct a clinical comparative study.
- Trial name
- NCT06941675
- Testing
- Hybrid Closed-Loop Artificial Pancreas System
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Shanxi Bethune Hospital
Polycystic Ovary Syndrome (PCOS), Metabolic Syndrome
Malay Women With PCOS and Their Association With Metabolic Syndrome
The abnormalities that characterize the Metabolic Syndrome (MetS) confer an increased risk of cardiovascular and other diseases.
- Trial name
- MPMSS (NCT03414957)
- Testing
- Hormonal and biochemical blood tests and ultrasound scanning
- Volunteers
- 210 people, healthy volunteers welcome
- Sponsor
- Cyberjaya University College of Medical Sciences
Liver Cancer, Pancreatic Cancer
YMN-136 Vaccine for Patients With Advanced Hepatobiliary and Pancreatic Malignancies
This study aims to determine the safety and maximum tolerated dose (MTD) of YMN-136 vaccine through a dose escalation trial, and to investigate whether YMN-136 vaccine can assist in the treatment of patients with advanced…
- Conditions
- Liver Cancer, Pancreatic Cancer, Biliary Tract Cancer (BTC)
- Trial name
- NCT07763301
- Testing
- YMN-136 vaccine
- Where
- China
- Volunteers
- 9 people
- Sponsor
- West China Hospital
Cancer of Pancreas, Cancer of the Pancreas
Adenocarcinoma of the Pancreas Treated With Panitumumab and Gemcitabine Regimen to Investigate Overall Survival as Primary Endpoint
This is a phase II, multi-center, open-label, single-arm clinical trial to be conducted in the United States. In approximately 55 centers, approximately 75 eligible locally advanced unresectable or metastatic pancreatic cancer…
- Conditions
- Cancer of Pancreas, Cancer of the Pancreas, Pancreas Cancer, Pancreatic Cancer
- Trial name
- APPRISE 1 (NCT00613730)
- Testing
- Gemcitabine, panitumumab
- Volunteers
- 3 people
- Sponsor
- Amgen
Type 2 Diabetes, Self-management
The Effect of Telephone Consulting on HbA1 and Self-Management
The aim of this study was to investigate the effect of telephone counseling (12 weeks) based on the Information, Motivation, Behavioral Skills (IMB) Model in patients with type 2 diabetes mellitus (T2DM) on self-management and…
- Trial name
- NCT04723628
- Testing
- Intervention group (telephone counseling)
- Where
- Turkey (Türkiye)
- Volunteers
- 63 people
- Sponsor
- Aksaray University
Ovarian Cancer
Phase Ib/II Study of Carboplatin + M6620 + Avelumab in PARPi-resistant Ovarian Cancer
The study was to evaluate the efficacy and safety of avelumab in combination with M6620 + carboplatin in participants with PARPi-resistant, recurrent, platinum sensitive ovarian, primary peritoneal, or fallopian tube cancer.
- Trial name
- NCT03704467
- Testing
- M6620, Avelumab, Carboplatin
- Where
- 13 sites in United States, Belgium and 1 more
- Volunteers
- 3 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Type 1 Diabetes
Audio Health Engagement Analysis in Diabetes: The AHEAD Study
Despite multidisciplinary care and advancements in therapeutics and technology, health outcomes remain suboptimal in pediatric diabetes centers world-wide.
- Trial name
- NCT01938807
- Testing
- CareCoach mobile application to assist in diabetes management
- Volunteers
- 43 people
- Sponsor
- University of California, San Francisco
Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men, Hot Flashes
A Study to Learn More About How Much of the Study Treatment Elinzanetant (or BAY3427080) Gets Absorbed, How Safe it is and How it Affects the Body in Healthy Female and Male Participants
Researchers are looking for a better way to treat men and women with vasomotor symptoms, a condition of having hot flashes caused by hormonal changes.
- Conditions
- Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men, Hot Flashes, Healthy Volunteers
- Trial name
- NCT05351892
- Testing
- Elinzanetant (BAY3427080)
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Bayer
Diabetes Mellitus
The Relative Bioavailability of INS068 Injection With Two Different Formulations in Healthy Subjects
The study is a single-centre, randomized, open, 2-period, 2-sequence crossover design clinical trial. It is planned to enroll 24 healthy male subjects. Subjects will receive INS068 injection on Day1 and Day8.
- Trial name
- NCT05336071
- Testing
- INS068 injection
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Type 2 Diabetes
Risk of CKD in Diabetic Patients With MAFLD
This cross-sectional study of 300 participants investigates the risk of chronic kidney disease (CKD) in individuals with metabolic dysfunction-associated fatty liver disease (MAFLD) and type 2 diabetes.
- Trial name
- NCT06304844
- Testing
- transient elastography (Fibroscan)
- Volunteers
- 300 people
- Sponsor
- Sohag University
Diabetes, Diabetes Mellitus, Type 1
Research Study Comparing Insulin Degludec to Insulin Detemir, Together With Insulin Aspart, in Pregnant Women With Type 1 Diabetes
The investigators are doing this study to see the effect of insulin degludec in pregnant women with type 1 diabetes, and if it is safe to use.
- Trial name
- EXPECT (NCT03377699)
- Testing
- Insulin degludec, Insulin Aspart, Insulin detemir
- Where
- 71 sites in Argentina, Australia and 13 more
- Volunteers
- 225 people
- Sponsor
- Novo Nordisk A/S
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.